NeuroBo Pharmaceuticals, Inc. Quarterly Debt-to-equity in % from Q1 2017 to Q2 2024

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: NeuroBo Pharmaceuticals, Inc. quarterly Debt-to-equity history and growth rate from Q1 2017 to Q2 2024.
NeuroBo Pharmaceuticals, Inc. Debt-to-equity for the quarter ending June 30, 2024 was 41.2 %, a 6.65% increase year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Growth (%)

Period	Value	YoY Chg	Change %	Date
Q2 2024	41.2	+2.57	+6.65%	Jun 30, 2024
Q1 2024	29.8	-15.2	-33.7%	Mar 31, 2024
Q4 2023	30.9	-2.51	-7.51%	Dec 31, 2023
Q3 2023	35.5	+19.5	+122%	Sep 30, 2023
Q2 2023	38.7	+21.9	+131%	Jun 30, 2023
Q1 2023	45	+28.5	+173%	Mar 31, 2023
Q4 2022	33.4	+18.6	+126%	Dec 31, 2022
Q3 2022	16	-6.17	-27.8%	Sep 30, 2022
Q2 2022	16.7	-7.96	-32.3%	Jun 30, 2022
Q1 2022	16.5	-11.2	-40.6%	Mar 31, 2022
Q4 2021	14.8	-24.6	-62.4%	Dec 31, 2021
Q3 2021	22.2	-8.59	-27.9%	Sep 30, 2021
Q2 2021	24.7	-83.9	-77.3%	Jun 30, 2021
Q1 2021	27.7	+87.5		Mar 31, 2021
Q4 2020	39.3	+60.8		Dec 31, 2020
Q3 2020	30.8	+41.4		Sep 30, 2020
Q2 2020	109	+160		Jun 30, 2020
Q1 2020	-59.8	+910	+93.8%	Mar 31, 2020
Q4 2019	-21.5	-148	-117%	Dec 31, 2019
Q3 2019	-10.7	-132	-109%	Sep 30, 2019
Q2 2019	-50.9	-180	-139%	Jun 30, 2019
Q1 2019	-970	-1.07K	-1030%	Mar 31, 2019
Q4 2018	126	+48.4	+62.4%	Dec 31, 2018
Q3 2018	122	+80.6	+197%	Sep 30, 2018
Q2 2018	129	+111	+636%	Jun 30, 2018
Q1 2018	104	+60.4	+137%	Mar 31, 2018
Q4 2017	77.7			Dec 31, 2017
Q3 2017	41			Sep 30, 2017
Q2 2017	17.5			Jun 30, 2017
Q1 2017	44			Mar 31, 2017

* An asterisk sign (*) next to the value indicates that the value is likely invalid.